ANAB - アナプティスバイオ （AnaptysBio Inc.）ANABのニュース
AnaptysBio Inc. (NASDAQ:ANAB) -3.56% Down Over Last Week, What Happens Next? 2023/01/28 13:30:00 Marketing Sentinel
In last trading session, AnaptysBio Inc. (NASDAQ:ANAB) saw 0.68 million shares changing hands with its beta currently measuring -0.11. Company’s recent per share price level of $24.11 trading at -$0.3 or -1.23% at ring of the bell on the day assigns it a market valuation of $669.05M. That closing price of ANAB’s stock is at … AnaptysBio Inc. (NASDAQ:ANAB) -3.56% Down Over Last Week, What Happens Next? Read More »
AnaptysBio Inc. (ANAB) Forecast: Revisiting The Past To Gain Insights For The Future 2023/01/27 15:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) concluded the trading at $24.41 on Thursday, January 26 with a fall of -1.97% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $24.90 and 5Y monthly beta was reading -0.03 with its price kept floating in the range … AnaptysBio Inc. (ANAB) Forecast: Revisiting The Past To Gain Insights For The Future Read More »
Investing in AnaptysBio Inc. (ANAB) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/24 13:32:00 US Post News
As of Monday, AnaptysBio Inc.’s (NASDAQ:ANAB) stock closed at $25.13, up from $25.00 the previous day. While AnaptysBio Inc. has overperformed by 0.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANAB fell by -19.22%, with highs and lows ranging from $34.33 to $18.20, whereas the […]
AnaptysBio Inc. (ANAB) deserves closer scrutiny 2023/01/16 18:24:00 US Post News
As of Friday, AnaptysBio Inc.’s (NASDAQ:ANAB) stock closed at $26.38, up from $23.07 the previous day. While AnaptysBio Inc. has overperformed by 14.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANAB fell by -24.09%, with highs and lows ranging from $35.22 to $18.20, whereas the […]
AnaptysBio rises 10% on stock repurchase of up to $50M 2023/01/13 14:39:47 Seeking Alpha
AnaptysBio (ANAB) said it had authorized a stock repurchase plan under which it can repurchase up to $50M common stock for $0.001 per share. (ANAB) rose ~10%. The company also…
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference 2022/08/05 20:00:00 GlobeNewswire
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.
AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option 2022/06/25 12:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 06/24/22, with the stock price up by 2.21% to the previous day’s close as strong demand from buyers drove the stock to $23.12. Actively observing the price movement in the last trading, the stock closed the session at $22.62, falling within a range of $22.18 and … AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option Read More »
An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior 2022/06/11 14:30:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) concluded the trading at $22.00 on Friday, June 10, with a fall of -3.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $22.72 and 5Y monthly beta was reading 0.13 with its price kept floating in the range … An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior Read More »
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference 2022/06/02 20:05:00 GlobeNewswire
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m. ET / 7:00 a.m. PT.
Short Volatility Alert: AnaptysBio, Inc. 2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Short Volatility Alert: AnaptysBio, Inc. 2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick 2022/05/14 18:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 05/13/22, with the stock price down by -0.38% to the previous day’s close as strong demand from buyers drove the stock to $21.13. Actively observing the price movement in the last trading, the stock closed the session at $21.21, falling within a range of $20.24 and … Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick Read More »
AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M 2022/05/04 21:41:48 Seeking Alpha
AnaptysBio press release (ANAB): Q1 GAAP EPS of -$1.31 misses by $0.32.Revenue of $0.97M (-91.4% Y/Y) misses by $4.08M.Shares -1.6% AH.Top-line data from the ongoing…
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update 2022/05/04 20:15:00 GlobeNewswire
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers 2022/04/28 12:48:05 Benzinga
AnaptysBio Inc (NASDAQ: ANAB ) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said that ANB032 demonstrated rapid … Full story available on Benzinga.com